Genovis AB (GENO.ST) Stock Analysis & Winston Score

Genovis is a Swedish biotechnology company that makes specialized enzymes and tools used by scientists in drug development and medical research. Its core products — sold under brands like SmartEnzymes — help researchers break down and analyze antibody-based medicines, which are a fast-growing class of drugs used to treat cancer and autoimmune diseases. The company's main customers are pharmaceutical companies, biotech firms, and academic research labs around the world. Genovis earns money by selling its enzyme products and research kits, a model that generates very high gross margins near 90%. The company is headquartered in Lund, Sweden, and sells globally, with a significant share of revenue coming from large pharmaceutical markets in North America and Europe. Its moat comes from highly specialized, hard-to-replicate enzyme technology that becomes embedded in customers' research workflows. The key growth driver is the continued expansion of antibody drug development worldwide, though the company faces risk from its relatively small size and dependence on a niche market.